Placenta-derived mesenchymal stem cells
New mesenchymal stromal cell lines from placental tissue for production of exosomes are now available! December 1st, 2021, Vienna, Austria Mesenchymal
New mesenchymal stromal cell lines from placental tissue for production of exosomes are now available! December 1st, 2021, Vienna, Austria Mesenchymal
We are proud to announce our participation in the LIVESAVER project November 25, 2021, Vienna, Austria The LIFESAVER project addresses the
Engineering of CD81 on extracellular vesicles to target specific cell surface proteins. September 17, 2021, Vienna, AustriaWe have developed a platform technology
MDimune and Evercyte form partnership for developing tumor-targeting EVs April 1, 2021, Seoul, Korea and Vienna, Austria MDimune Inc. and Evercyte GmbH announced a
Knock-out of CD46 in RPTEC/TERT1 cells Application: gene editing of human telomerized cells with CRISPR/Cas9 knock-out of CD46 in RPTEC/TERT1 cells using CRISPR
Overexpression of green fluorescent protein in endothelial cells Application: establishment of reporter cell lines from relevant and standardizable telomerized human cells transfection
Scratch assay for monitoring skin cell proliferation / migration screening for substances that induce fibroblast growth application: identification of agents with potential to target impaired
Analysis of miRNA cargo of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells WJ-MSC/TERT273 application: characterization and quality control for stable production of extracellular
Study of myofibroblast differentiation monitoring the effect of exogenous factors on myofibroblast differentiation in a model using TGFß as inducer of alpha smooth muscle actin in fibroblasts
3D spheroid assay for screening of angiogenesis modulators monitoring the effect of exogenous factors on sprout formation from endothelial spheroids as a measure for induction / inhibition